Campos José Luis, Pons Gemma, Al-Sakkaf Ali M, Lusetti Irene Laura, Pires Laura, Vela Francisco Javier, Ramos Elena, Crisóstomo Verónica, Sánchez-Margallo Francisco Miguel, Abellán Elena, Masiá Jaume
Department of Microsurgery, Jesús Usón Minimally Invasive Surgery Centre, 10071 Cáceres, Spain.
Department of Plastic Surgery, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
J Funct Biomater. 2024 Aug 21;15(8):235. doi: 10.3390/jfb15080235.
Lymphedema presents significant challenges to patients' quality of life, prompting the exploration of innovative treatments, such as collagen scaffolds, aimed at treating and reducing the risk of lymphedema. We aimed to evaluate the preventive and therapeutic efficacy and the lymphangiogenic potential of implanted aligned nanofibrillar collagen scaffolds (BioBridge) following the induction of secondary lymphedema in a rabbit model. Thirty rabbits were divided into treatment (G1), prevention (G2), and control (G3) groups. Secondary lymphedema was induced in all groups. BioBridge implantation was performed in G2 and G1 on days 0 and 60, respectively. Follow-ups included hindlimb circumference measurements and indocyanine green lymphography at 0, 60, and 90 days. None of the study rabbits exhibited dermal backflow on day 0 before surgery. At 60 days, the incidence rates of dermal backflow in G1, G2, and G3 were 100%, 44.4%, and 90%, respectively. Furthermore, at 90 days, the incidence rates were 22.2%, 44.4%, and 90%, respectively. New linear lymphatic observation was seen in rabbits with resolved dermal backflow. The findings of this study demonstrated the capacity of BioBridge scaffolds to induce new lymphatic vessel formation and reduce dermal backflow in secondary lymphedema in a rabbit model.
淋巴水肿给患者的生活质量带来了重大挑战,促使人们探索创新治疗方法,如胶原蛋白支架,旨在治疗和降低淋巴水肿的风险。我们旨在评估在兔模型中诱导继发性淋巴水肿后,植入的定向纳米纤维胶原蛋白支架(BioBridge)的预防和治疗效果以及淋巴管生成潜力。30只兔子被分为治疗组(G1)、预防组(G2)和对照组(G3)。所有组均诱导继发性淋巴水肿。分别在第0天和第60天对G2和G1进行BioBridge植入。随访包括在第0、60和90天测量后肢周长和进行吲哚菁绿淋巴造影。术前第0天,所有研究兔均未出现皮肤反流。在第60天,G1、G2和G3的皮肤反流发生率分别为100%、44.4%和90%。此外,在第90天,发生率分别为22.2%、44.4%和90%。在皮肤反流消失的兔子中观察到新的线性淋巴管。本研究结果表明,BioBridge支架能够在兔模型中诱导继发性淋巴水肿中形成新的淋巴管并减少皮肤反流。